EZH2 and non-small cell lung carcinoma: EZH2 has a well-defined oncogenic role in cancer initiation, progression, metastasis, metabolism, and drug resistance and in the modulation of anti-tumor immunity in cancers of the prostate, breast, bladder, and esophagus, as well as gastric and non-small-cell lung carcinoma and lymphomas [18,27,28,29,30,31].